ASCO 2022: What Factors May Contribute to Asparaginase-Associated Toxicities During ALL Induction Therapy?
Posted: 07/07/2022 | By: Sarah Campen, PharmD

Asparaginase is a key tool used in regimens to treat both pediatric and young adult patients with acute lymphoblastic leukemia (ALL). There are side effects associated with the agent, however, and in a study presented by Orgel et al at the 2022 ASCO Annual Meeting, a group of researchers sought to determine what factors may increase the likelihood of the development of asparaginase-associated toxicities.

Question 1 of 5

Based on the study results, what did the study authors conclude regarding dosing of asparaginase?

Choose 1